Biotricity ( (BTCY) ) has released its Q2 earnings. Here is a breakdown of the information Biotricity presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biotricity Inc. is a Nevada-based company specializing in remote monitoring technology for preventative healthcare, focusing on real-time data collection and analysis to aid medical professionals. In its latest earnings report, Biotricity highlighted a notable increase in revenue, reaching $3.27 million for the quarter ended September 30, 2024, a rise from $2.89 million in the same quarter of 2023. The company’s gross profit also improved to $2.46 million from $1.99 million year-over-year. Despite these gains, Biotricity reported a net loss of $1.56 million for the quarter, reflecting ongoing operational and research expenses. The company’s total liabilities decreased slightly to $34.17 million from $35.92 million at the end of March 2024. Looking ahead, Biotricity’s management remains focused on expanding its product offerings and increasing its market presence, with expectations of continued revenue growth and improved liquidity through strategic business development and capitalization efforts.